Prescription Drugs and Pharmacy News

TUSTIN, CA–(Marketwire – December 13, 2010) – Through its subsidiary AMDL Diagnostics Inc., Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic (IVD) cancer tests, announced today it has entered into a five-year full-service distribution agreement with Naroo Ditech Inc. to expand the Company’s Onko-Sure® IVD cancer test throughout the Korean healthcare market.

Under the terms of the agreement, Naroo Ditech has committed to purchase a minimum of 3,352 Onko-Sure® test kits over the duration of the partnership. Naroo Ditech will represent RPC while obtaining regulatory clearances and providing marketing, sales, and distribution services for Onko-Sure® in diagnostic centers and clinical labs throughout the Korean market.  Marketing, sales and distribution services include developing product localization strategies; representing Radient Pharmaceuticals and its Onko-Sure® IVD cancer test at relevant healthcare conferences and events; incorporating relevant product information on the Naroo corporate website. Additionally, Naroo Ditech will provide a dedicated customer service team to respond to customer inquiries and technical questions.

RPC’s Chairman and CEO Douglas MacLellan commented on today’s news, stating, “We are extremely pleased to have finalized our sales, marketing and distribution partnership with Naroo and anticipate this agreement will significantly expand the commercialization of Onko-Sure® in the Korean market. One of Naroo’s key strategies is to market Onko-Sure® as a screening test for industrial workers at Korea’s largest manufacturers, such as Hyundai. This latest agreement adds to our expanding list of global distributors, through which RPC is working to grow product sales and revenues.”

Onko-Sure® is a simple, noninvasive, patent-pending and regulatory-approved in vitro diagnostic test that enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise dramatically with the progression of cancer. Onko-Sure® is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada for lung cancer detection and treatment monitoring.

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.radient-pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

RESEARCH TRIANGLE PARK, NC–(Marketwire – December 9, 2010) – As many companies put the finishing touches on their 2011 Action Plans, the pharmaceutical and biotechnology sectors are looking to create opportunities from the challenges of recent years.

Cutting Edge Information, Inc. analyzed what issues its clients have studied most closely in 2010 and the resulting decisions and strategies they are likely to implement in 2011. “The popularity of each topic shows the areas that companies consider most important as they enter 2011,” said Jason Richardson, president of Cutting Edge Information.

“These are the areas executives believe offer both challenges and opportunities that can provide competitive advantage if managed well in the next year.”

The lists below include both the subject areas identified by industry executives and the top project conducted by Cutting Edge Information (http://www.cuttingedgeinfo.com/) for that functional group.

Top 3 Medical Affairs Reports
#1 Thought Leader Fair-Market Value: Compensation Benchmarks and Procedures
#2 Medical Science Liaison Programs — The New MSL Profile: Internal Thought Leader, External Voice and Clinical Catalyst
#3 Pharmaceutical and Medical Device Regulatory Affairs

Top 3 Clinical Development Reports
#1 Benchmarking Drug Safety and Pharmacovigilance
#2 Streamlining Clinical Trials
#3 Clinical Trial Patient Recruitment

Top 3 Decision Support and Forecasting Reports
#1 Oncology Market Forecast to 2015
#2 Strategic Pharmaceutical Competitive Intelligence
#3 Diabetes Market Forecast to 2015

Top 3 Market Access Reports
#1 Health Economics and Outcomes Research
#2 Securing Market Access: Reimbursement, Payer Relationships and Healthcare Reform
#3 Outcomes-Based Pharmaceutical Pricing: Meeting Stakeholder Needs

Top 3 Portfolio Planning and Business Development Challenges
#1 Lifecycle Management: Strategy, Selection and Execution
#2 Pharmaceutical and Biotechnology Business Development: Accelerating the Deal
#3 Pharmaceutical Alliance Management

Top 3 Marketing and Commercialization Reports
#1 Countering Generics and Biosimilar Threats
#2 Pharmaceutical Speaker Programs
#3 Driving Successful Pharmaceutical Brands

Cutting Edge Information will continue to analyze key trends emerging from 2010 and impacting 2011 and beyond. More detail and background about Cutting Edge Information is available through the pharmaceutical Twitter feed, the life sciences research and consulting LinkedIn page, and a set of complimentary newsletters providing new management analysis monthly.

Click here to see all recent news from this company

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Dec. 8, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (the “Company” or “ALDA”) announces that it is undertaking a non-brokered private placement of up 2,000,000 units of the Company (the “Units”) at a price of $0.10 per Unit for proceeds to the Company of up to $200,000. Each Unit will consist of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.20 per common share for a period of 24 months from the date of the issuance of the purchase warrant with a forced exercise provision attached to each warrant commencing on the day following the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Company exceeds $0.40 then the exercise period of the warrants will be reduced to a period of 10 days following such trading days.

Certain insiders of the Company have been selling common shares of ALDA through the facilities of the TSX Venture Exchange in connection with this private placement and will reinvest up to $175,000 of the proceeds in the private placement. Accordingly, insiders of ALDA will be subscribing for over 25% of the offering, constituting a related party transaction pursuant to Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9 which is exempt from the requirement to obtain an independent valuation pursuant to Section 5.5(b) of MI 61-101 and the requirement to obtain minority shareholder approval pursuant to Section 5.7(1)(b) of MI 61-101.

The offering is being made on a private placement basis pursuant to registration and prospectus exemptions of applicable securities laws and is subject to acceptance by the TSX Venture Exchange. All securities issued will be subject to a four month restricted period and will bear a restrictive legend accordingly. Net proceeds from the offering will be used for working capital purposes.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the “Act”) and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

SCOTTSDALE, AZ–(Marketwire – December 7, 2010) – miCARD and Gold Wing Road Riders Association, the world’s largest social organization for owners and riders of Honda Gold Wing/Valkyrie motorcycles have partnered to provide GWRRA with a co-branded, medical information card that prepares association member/riders for an unanticipated medical emergency.

“One of the highest priorities at GWRRA is to ensure the health and safety of our 74,000+ members,” said Ed Price, Marketing Director at GWRRA. “We are pleased to join forces with miCARD to ensure our association riders are prepared for any kind of a medical event. No matter where our members go, we know that the lifesaving medical information on miCARD will be with them. I personally carry miCARD in my wallet all the time, as I travel extensively.”

Motorcycle Fatalities on the Rise
The National Highway Transportation Safety Administration projects more than 100,000 motorcycle injuries will occur this year alone. Even with the advent of statewide motorcycle safety campaigns to help automobile drivers become more aware of motorcyclists, fatalities continue to rise. Carrying medical information ensures that emergency personnel have the critical information they need to make lifesaving decisions should an accident occur.

miCARD is the only medical information card and online Personal Health Record(PHR) designed by an emergency physician. In less than one minute, miCARD gives medical personnel in the field a readable summary of a member’s vital medical information. This includes: current medical conditions, critical medications, emergency contacts, allergies and more. miCARD’s wallet card is further supported by an online PHR which stores additional member information such as: advance directives, physician contacts, EKG’s, lab results, and current medications. All personal medical information is stored securely online and viewable at the miCARD website 24/7 by treating medical providers worldwide.

“Critical decisions about your health are made in the first few minutes of your emergency care,” said Dr. James Kelley, a practicing ER physician and co-founder of miCARD. “If you are unconscious or incapacitated, medical personnel have no knowledge of your existing medical conditions, critical medications or other important details which could impact your care and save your life.”

miCARD is a low cost solution to the problem of emergency preparedness and care and can be created securely online in minutes. To ensure the health and safety of your association members or to enquire about co-branding opportunities with miCARD please visit www.micard.com/partners or contact us directly at (866)596.2956.

About miCARD
Headquartered in Scottsdale, AZ, miCARD is a physician designed, medical information card and online personal health record designed to optimize emergency medical care. miCARD’s proprietary solution improves the flow of critical care information and ensures medical personnel have immediate and secure access to a user’s vital medical information, 24/7 worldwide. miCARD is registered with the USPTO under patent & trademark protection. For more information about miCARD please visit www.micard.com or contact us at (866)596.2956.

About Gold Wing Road Riders Association
 Founded in 1977, The Gold Wing Road Riders Association (GWRRA) is the world’s largest single-marque social organization for owners and riders of Honda Gold Wing/Valkyrie motorcycles. Dedicated to our motto, Friends for Fun, Safety and Knowledge, GWRRA members enjoy the freedom of belonging to a not-for-profit, non-religious and non-political organization with more than 800 active chapters, serving nearly 80,000 U.S., Canadian and international members in 53 foreign countries.

SAN DIEGO, CA–(Marketwire – December 7, 2010) – Adamis Pharmaceuticals Corporation (OTCBB: ADMP) announced the successful completion of a Phase 3 contraceptive trial of the company’s contraceptive gel product candidate named Savvy® (C31G). The study met its primary endpoint and was conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), in the Contraceptive Clinical Trials Network at 14 sites in the United States. The results of the NICHD study are published in Obstetrics and Gynecology, v.116, pages 1265-1273, in December, 2010.

The Phase 3 trial was a randomized, double-masked, controlled comparator study to assess whether a gel containing the spermicide, C31G, was non-inferior to Conceptrol®, a commercially available product containing nonoxynol-9 (N-9). The clinical investigators found that C31G was not inferior in contraceptive efficacy to the comparator drug Conceptrol®. Thus, the study met its primary objective. Moreover, the gel was well-tolerated and had a high degree of acceptability in women who completed the study. No drug-related serious adverse events were observed with C31G. Drug-related side effects of C31G were generally mild and did not lead to discontinuation.

Currently, all spermicides commercially available in the U.S. contain the active ingredient N-9 in a carrier such as a gel, film, cream, foam, suppository, or tablet. N-9 has been reported in some studies to cause irritant and allergic reactions in some users. Although the Conceptrol® product was effective and well-tolerated in the NICHD comparative trial, there were a significantly lower number of drug-related events with the C31G gel and fewer women discontinued the study due to drug-related side effects. In an interview with Reuters Health, lead researcher Dr. Anne E. Burke of The John’s Hopkins School of Medicine stated, “There are concerns with nonoxynol-9, such as vaginal side effects and genital irritation for some users. It seems that C31G might offer improvements in those regards.” C31G does not contain nonoxynol-9 and, if commercialized, may offer a welcome alternative for women who seek a non-hormonal method of contraception. 

C31G previously was the subject of two Phase 3 clinical trials conducted in Africa, supported by Family Health International and the United States Agency for International Development, to determine whether C31G was safe and effective for reducing women’s risk of acquiring HIV infection. The external independent Data Monitoring Committee reviewing those trials concluded in 2005 and 2006 that, while there were no safety concerns based on the results of the studies to date, continuing the trials would not allow the effect of C31G on HIV acquisition to be determined because of a lower than expected rate of HIV seroconversion in the trials. The committee determined that continuation of the trials was not warranted due to a lack of statistical significance between C31G gel and the vehicle control in the interim data. Accordingly, the trials were discontinued.

Adamis estimates that the market for a product with the characteristics of C31G to be in the $500 million range. Dr. Dennis J. Carlo, President and CEO, stated, that “Since the product does not fit in the core business of the company, Adamis is currently evaluating various out-licensing opportunities. We are currently in discussions with multiple organizations that have a focus or business unit in the area of contraception.”

About Adamis Pharmaceuticals

Adamis Pharmaceuticals has three wholly-owned subsidiaries: Cellegy Holdings, Inc.; Adamis Corporation; and Biosyn, Inc. Adamis Corporation has two wholly-owned subsidiaries, Adamis Laboratories and Adamis Viral Therapies. Adamis Labs has niche prescription products in the allergy and respiratory therapeutic area and intends to launch additional products in this area. Adamis Viral Therapies is focused on the development of patented, proprietary technologies for the potential treatment of human prostate cancer.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations or future financial performance, including, but not limited to the following statements: the company’s ability to successfully develop and market C31G assuming it is approved for marketing by the FDA and other regulatory authorities; regulatory issues or delays with the FDA; and the intellectual property protection that may be afforded by any patents or patent applications relating to C31G. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis’ actual results to be materially different from these forward-looking statements. These risks and uncertainties include, but are not limited to: whether C31G will be approved for marketing by the FDA and other regulatory authorities; whether the company will be able to obtain required funding to pursue activities relating to C31G; whether C31G is a commercially viable product and can be commercialized, manufactured, and marketed in a cost-effective manner; the extent of consumer demand for any such product; and whether any third party will be interested in entering into agreements relating to development and marketing of C31G. It is uncertain whether C31G will ever be commercialized or whether the company will ever realize revenues therefrom. Certain of these risks, uncertainties, and other factors, as well as other risks and uncertainties relating to the company’s business are described in greater detail in Adamis’ filings from time to time with the SEC, all of which are available free of charge on the SEC’s web site at http://www.sec.gov. Adamis expressly disclaims any intent to update any forward-looking statements.

TUSTIN, CA–(Marketwire – December 7, 2010) –   Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) in partnership with Jaiva Technologies, today announced the formation of NuVax Therapeutics, Inc. (“NuVax”) — a wholly owned subsidiary of Radient Pharmaceuticals. The formation of NuVax Therapeutics is a strategic move on the part of RPC to enhance the Company’s Q2 2010 collaboration agreement with U.S.-based Jaiva Technologies — a biotechnology company focused on the research and development, distribution, marketing and sales of promising third?party healthcare technology products. 

NuVax, a clinical stage pharmaceutical company, aims to develop novel immune-gene therapeutics that have the potential to significantly impact and extend the quality of life for cancer patients. Through the newly formed NuVax Therapeutics, RPC and Jaiva Technologies will utilize RPC’s Combined Immunogene Therapy (“CIT”) cancer therapy to carry out human phase II clinical trials and develop products that will be first in-line therapies for largely unmet medical needs for cancer. The rights to RPC’s CIT technology are anticipated to be transferred to NuVax and 100% of future product development and commercialization, including the development and in-licensing of the up to five additional cancer-fighting technologies will be managed through NuVax under the leadership of Jaiva Technologies Founder, President and CEO Dr. Umesh Bhatia. Dr. Bhatia’s team will be responsible for engagement with clinical laboratories, hospitals and physicians in multiple international locations; conducting clinical trials for CIT technology; securing government approval for the use of CIT as a cancer therapy and vaccine throughout select markets; expansion and management of stage II clinical trials in multiple international locations including the U.S.; and full commercialization of CIT and all other in-licensed therapies in other select international markets. 

In 2001, RPC acquired CIT for approximately US$2 million in cash. The Company has since invested approximately US$1 million in additional capital for patent protection with a U.S. patent issued May 25, 2004. Developed by Dr. Lung-Ji Chang, CIT is a cancer therapy that works by simultaneously incorporating two genes directly into a patient’s tumor cells to enhance their immune system’s natural ability to destroy other cancer cells. CIT targets cancer cells for immunological attack while simultaneously stimulating a stronger immune response against the tumor cells. Dr. Chang currently serves as a consultant to RPC for the continued development of CIT and other gene therapies.

According to RPC Chairman and CEO Mr. Douglas MacLellan, “The formation of NuVax Therapeutics provides a unique platform to significantly accelerate and expand our planned collaboration with Jaiva Technologies, specifically as it relates to the commercialization of CIT, in-licensing new cancer therapies and conducting stage II human clinical trials to ultimately introduce these products to market. Simultaneously, it allows us to dedicate RPC resources to the continued worldwide commercialization of our Onko-Sure In Vitro Diagnostic cancer test. Together we anticipate success through both Companies to drive long-term growth and shareholder value.”

To support the growth and success of NuVax, RPC and Jaiva Technologies have established an internationally renowned executive and scientific team and board of directors that include RPC Chairman and CEO Mr. Douglas Maclellan, RPC COO and Chief Financial Officer Mr. Akio Ariura, Jaiva Technologies Founder, President and CEO Dr. Umesh Bhatia, RPC Board member Mr. Michael Boswell, Dr. Lung-Ji Chang, Professor of Molecular Genetics and Microbiology at the University of Florida Gainesville, and Dr. Afsaneh Motamed-Khorasani, Director of Oncology at RPC.

New to the team is Dr. Donald P. Francis — Dr. Francis worked for CDC from 1971 to 1992: smallpox (assigned to WHO) in India, Bangladesh, Sudan and the former Yugoslavia, cholera in Nigeria, Ebola in Sudan, Assistant Director, Hepatitis Division, Assistant Director, Virology Division. From 1981 he worked on HIV/AIDS: Coordinator of Laboratory Activities (Atlanta), Consultant to State of California (Berkeley) and San Francisco Mayor’s office. His AIDS efforts were chronicled in And the Band Played On, by Randy Shilts. In 1993 he joined Genentech where his HIV vaccine work began. In 1995, Dr. Francis co-founded a spin-off of Genentech called VaxGen where the world’s first efficacy trials were completed in the United States, Canada, Holland and Thailand. In 2004, Dr. Francis retired from VaxGen to establish a not-for-profit foundation, Global Solutions for Infectious Diseases, dedicated to developing vaccines for the less developed parts of the world. In 2009, the first successful HIV vaccine trial was reported. That trial used GSID’s vaccine combined in a “prime-boost format” with one from Sanofi. In addition to HIV, Dr. Francis works with international vaccine manufacturers on vaccines for dengue and influenza. He is a frequent consultant for WHO. Dr. Francis is anticipated to serve as an advisor and member of NuVax’s Board of Directors of NuVax.

After completing undergraduate studies at the University of California at Berkeley, Dr. Francis received his M.D. from Northwestern University and his Doctor of Science in Virology from Harvard. In addition, he completed his pediatric training at the University of Southern California Medical Center in Los Angeles and his infectious disease training at Harvard.

About Jaiva Technologies
Jaiva Technologies is a US?based biotechnology company founded by Dr. Umesh Bhatia that is focused on the research and development, distribution, marketing and sales of promising third?party healthcare technology products, including RPC’s CIT cancer therapy and vaccine.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

SAN DIEGO, CA–(Marketwire – December 7, 2010) – Medistem Inc. (PINKSHEETS: MEDS) announced today the appointment of Dr. Vladimir Bogin as President and Chairman of the Board, Dr. Sergey Sablin as Vice President and Board Member, and Vladimir Zaharchook as Vice Chairman of the Board and Board Member. These changes were brought about as the result of a stock purchase agreement changing majority ownership of the company. 

“Dr. Sablin, who has a track record of excellence in drug discovery and development, is a founder of Selena Pharmaceuticals and a co-founder of Medivation, companies that advanced Dimebon, a Phase III technology that resulted in a deal with Pfizer with an over $200 million in the upfront payment. Dr. Bogin, a licensed physician with training from Brown and Yale, founded the contract research organization (CRO) Cromos Pharma, and has held Director-level positions with Big Pharma. Mr. Zaharchook is a successful businessperson and strategist. I am happy to entrust the future of our company in the hands of these experienced professionals,” said Dr. Neil Riordan, founder and former President and Chairman of Medistem, who resigned along with board member Dr. Roger Nocera as part of the acquisition. Dr. Riordan remains a shareholder and collaborator of Medistem. 

Medistem was founded in 2005 by Dr. Riordan as a developer, licensor, and licensee of adult stem cell therapeutics. To date technologies developed by Medistem have been used in more than 900 patients internationally. Currently Medistem, together with the Indiana company General Biotechnology, is nearing completion of additional experiments requested by FDA to allow for clinical trial initiation as part of its filed IND BB-13898 covering the use of Medistem’s “Endometrial Regenerative Cell” (ERC) product in patients at risk of amputation. 

ERC are a novel stem cell population isolated from menstrual blood that the company has demonstrated is capable of generating heart, brain, lung, liver, pancreatic, bone, muscle, blood vessel and cartilage tissue. Advantages of ERC include: a) lack of need for donor matching, allowing for “off the shelf” use; b) ability to be injected intravenously; and c) economical production in large scale.

“Dr. Riordan has pioneered the development of practical stem cell based products for treatments of debilitating conditions ranging from Multiple Sclerosis, to Duchenne Muscular Dystrophy, to Heart Failure. The intellectual property portfolio for these products, which are the basis of Medistem’s US-based developmental efforts, provide a deep pipeline of therapeutic candidates,” said Dr. Bogin.

“In contrast to companies who perform research for the sake of research, Medistem’s technologies are actually benefitting patients today, unfortunately only outside of the US. I was attracted to Medistem’s desire to make these treatments available to patients through the tried and tested FDA regulatory route,” said Mr. Zaharchook.

“The fact that Medistem’s ERC cells can be shipped to any facility in the US and administered without need for complex cell processing or injection procedures makes this stem cell product very attractive from a commercialization perspective,” said Dr. Sablin.

About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. 

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

id=”nav_links”>

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Dec. 2, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (the “Company”) announces that new tests have shown that T³6^® Antiseptic Hand Sanitizer is completely effective against two types of new “superbugs” within 15 seconds. The testing was conducted at BioScience Laboratories in Bozeman, MT against antibiotic-resistant strains of E. coli and Klebsiella. These strains have taken genes from other bacteria that have developed the ability to digest nearly all antibiotics, including penicillin-like antibiotics that possess broad spectrum antibacterial properties and are typically used as a last resort. Such genetic “swapping” is common among bacteria and is a major cause of antibiotic resistance.

Dr. Terrance Owen, President & CEO comments, “T³6^® Antiseptic Hand Sanitizer works in a completely different way than antibiotics. It kills infectious organisms by disrupting their cell walls so the presence of antibiotic-digesting enzymes does not stop it from working. Since these infections are so dangerous, it is important to prevent them from happening in the first place. Proper hygiene, including the use the of hand sanitizers and disinfectants such as T³6^® Antiseptic Hand Sanitizer and T³6^® Disinfectant, is a very important step in preventing the spread of potentially incurable diseases.”

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The Company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA
President & CEO
ALDA Pharmaceuticals Corp.
www.aldacorp.com

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the “Act”) and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Dec. 1, 2010) – Premier Diagnostic Health Services Inc. (CNSX:PDH) (“PDH”) announces the offering of two non-brokered term sheets to raise a total of $350,000.

The two non-brokered term sheets: “Offering A” and “Offering B” are offered to accredited investors.

1. Offering A consists of 625,000 Units at $0.40 per Unit, each Unit consisting of one Share and one half Warrant, with a minimum subscription of 125,000 Units for $50,000, for a total Offering of $250,000. One Half Warrant is included with each Unit; a full Warrant entitles the holder to subscribe for a further Share of PDH for $0.60 per Share. Warrants will be non-transferable and will expire on June 30, 2011.

2. Offering B consists of 250,000 Shares of Premier Diagnostic Health Services Inc. (“PDH”) to raise a total of $100,000. The price per Share is $0.40.

Both “A” and “B” Offerings will expire at 5:00 p.m. on December 20, 2010.

The proceeds from the term sheets will be used to:

1. Identify a second hospital in the metropolitan area of Beijing, China (in addition to PDH’s already established Center), for the establishment and joint operation of a Center for Advanced Diagnostics using PET-CT scanning for the diagnosis of cancer, with the objective of entering into a definitive agreement within three months;
2. Identify between one and three hospitals in the Pearl River Delta region of Guangdong province, China, particularly in the metropolitan area of Guangzhou, for the establishment and joint operation of Centers for Advanced Diagnostics using PET-CT scanning for the diagnosis of cancer, with the objective of entering into definitive agreements within six months; and
3. General working capital purposes.

The non-brokered private placement offering announced November 3, 2010 was not proceeded with.

About Premier Diagnostics Health Services Inc. (CNSX:PDH)

As leaders in advanced health and education with the international medical community, PDH is rolling out its global strategy of establishing a network of Centres for Advanced Diagnostics in Canada and China. By utilizing MRI and PET-CT, the most advanced medical diagnostic imaging technology available and the production of FDG, the radiopharmaceutical tracer used in oncology PET procedures; PDH is uniquely positioned to deliver continued innovation, growth and profitability.

DEURLE, BELGIUM–(Marketwire – November 30, 2010) – Remedent, Inc. (OTCBB: REMI), an international company specializing in research, development and the manufacture of oral care and cosmetic dental products signed an agreement with Small Caps Finance SA to open at least two Glamsmile Studios in Brussels, Belgium and Milan, Italy with an option for Rome, Italy as well.

SCF will provide all the necessary financing to a joint venture between both entities, where Remedent/Glamsmile will be the majority owner and provide all the necessary product and support to open the Studios. Glamsmile will operate and manage the Studios under the same formula for success as it does in Europe and Asia. It is anticipated that both Studios will open prior to the conclusion of our year end, namely March 31, 2011.

“The direct retail model of opening Studios in both Asia and Europe has been the reason for our financial turnaround as opposed to our previous wholesale (B2B) model via a distributor. This has led to two consecutive profitable quarters since the beginning of our financial year, April 1, 2010. In addition to western Europe, we will continue with our Glamsmile Studio expansion in Asia as well where we anticipate opening our Shanghai superstore in early 2011. I am very excited about our new venture with SCF for western Europe which will give us further exposure into two new markets, namely Milan and Brussels. The locations for our two new Studios have already been determined and they will be based in the most affluent shopping areas of both major cities. I look forward to the opening of both these two new locations where we expect the financial success to continue as we have experienced with our other Studios located in both Europe and Asia,” said Guy DeVreesse, the CEO of Remedent.

SCF currently has investments in both the pharmaceutical and health care industries. “The Glamsmile concept is unique and we are very excited about introducing beautiful smiles into new markets,” said Mr. Bernardo Ruzziconi, SCF, Chief Executive Officer.

About Remedent.

Remedent, Inc. specializes in the research, development, manufacturing and marketing of oral care and domestic dentistry products. The company serves the professional dental industry with breakthrough technology for dental veneers. These products are supported by a line of professional veneer whitening and teeth sensitivity solutions. Headquartered in Belgium, Remedent distributes its products to more than 35 countries worldwide. For more information, go to www.remedent.com

Forward-Looking Statements

Statements in the press release that are “forward-looking statements” are based on the current expectations and assumptions that are subject to risks and uncertainties. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Remedent’s actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “believes,” “belief,” “expect”, “intends,” “anticipate,” “anticipates,” “plans,” “projects,” “project,” to be uncertain and forward looking. Actual results could differ materially because of facts such as Remedent’s ability to achieve the synergies and value creation contemplated by the proposed transaction. For further information regarding risks and uncertainties associated with Remedent’s business, please refer to the risks described in Remedent’s filings with the Securities and Exchange Commission, including but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. We undertake no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of the press release.

TUSTIN, CA–(Marketwire – November 30, 2010) – Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the signing of a Letter of Intent (“LOI”) to form an exclusive distribution agreement and collaborative business development partnership with Colombia-based PROCAPS S.A. PROCAPS is a top tier Latin American healthcare distribution company currently commercializing oncology and other therapeutic products throughout countries in Latin America.

RPC and PROCAPS intend to structure a long-term exclusive distribution partnership to build market share and awareness for RPC’s U.S. FDA-cleared Onko-Sure® In Vitro Diagnostic (IVD) cancer test in Latin America. The Companies are working on the following terms:

• RPC and PROCAPS will evaluate strategies to commercialize RPC’s Onko-Sure® IVD cancer test as a medically and economically beneficial cancer test for patients in Colombia and other Latin American healthcare markets.
• PROCAPS will investigate the market opportunity for full-service distribution of RPC’s Onko-Sure® IVD cancer test kit to clinical reference labs, hospitals and cancer treatment centers in designated territories in Latin America.
• RPC will grant PROCAPS first rights for distribution of Onko-Sure® in Colombia, Venezuela, Peru, Ecuador, Bolivia, Panama, Guatemala, Dominican Republic, and El Salvador.

In selecting PROCAPS, RPC acknowledges the Company’s expertise in launching new healthcare products in key Latin American markets. PROCAPS has formed successful partnerships with large pharmaceutical companies including Wyeth, Merck, GSK, and Sanofi. Most recently, PROCAPS has become an exclusive distributor of a US-developed oncology therapeutic.

RPC Chairman and CEO Mr. Douglas MacLellan commented, “Cancer knows no borders, and Radient Pharmaceuticals is well positioned to combat this disease by supplying innovative diagnostic tests like Onko-Sure® on both a domestic and global level. Latin America has an escalating cancer challenge similar to other emerging economies and in working with PROCAPS S.A., RPC holds tremendous commercialization potential for the rapidly expanding Latin American healthcare market. We are eager to finalize our partnership with PROCAPS and begin the marketing and sales of Onko-Sure in this region.”

For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

WINNIPEG, MANITOBA–(Marketwire – Nov. 22, 2010) – DiaMedica (TSX VENTURE:DMA) today announces that in accordance with the terms of the warrant indenture for those warrants issued on June 30, 2010 the Company has provided the required written notice to holders of such warrants that the expiry date has been accelerated to the close of business December 22, 2010.

Under the terms of the indenture and the broker warrant certificates, if the 10-day volume weighted average trading price of the common shares of DiaMedica on the TSX Venture Exchange exceeds $0.75, then at any date subsequent to this date, the expiry date of the warrant shall be the day that is 30 days following the later of (i) the date that written notice of the accelerated expiry is sent to warrantholders; and (ii) the date on which the announcement of the warrant expiry acceleration is made by news release. As of the close of business on November 19, 2010, the 10-day volume-weighted average trading price of the common shares exceeded $0.75. Warrants may be exercised through payment of the exercise amount of $0.50 per full warrant up to the close of business on December 22, 2010. If all of the 6,215,000 outstanding warrants subject to this acceleration are exercised, DiaMedica will receive additional proceeds of $2.8 million. Any warrants not exercised prior to the accelerated expiry date and time will expire without any further action being taken.

About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing novel treatments for type I diabetes, type 2 diabetes and other disorders. DiaMedica has completed two successful proof-of-concept II studies with DM-71 and DM-99, which demonstrate human efficacy in lowering blood glucose levels in patients with type 2 diabetes.

DiaMedica’s lead product DM-199 is a novel next generation recombinant form of DM-99, which has shown the potential to increase insulin sensitivity, reduce the autoimmune attack and trigger proliferation of pancreatic beta cells, neural stem cells and bone marrow cells. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”. For further information please visit www.diamedica.com.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the anticipated use of proceeds from the Offering, management’s assessment of DiaMedica’s future plans, information with respect to the advancement of DiaMedica’s research and development programs, and DiaMedica’s other estimates and expectations. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our research and development programs, the availability of additional financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters.
Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2009 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions, which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of additional financing for research and development companies, and general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. Additional risk factors, factors which could cause actual results to differ materially from expectations, and assumptions relating specifically to our acquisition of Sanomune may be found in our press releases dated February 18, 2010 and April 20, 2010.

WALNUT CREEK, CA–(Marketwire – October 28, 2010) –  Dr. Mark Wolpa, founder of the Bay Area Foot & Laser Podiatry Group, is proud to announce that the PinPointe laser has received official FDA clearance for the treatment of toenail fungus. PinPointe™ is the first and only laser to receive this coveted FDA clearance specifically for treating toenail fungus, an embarrassing infection that causes a thickening and yellowing of the toenails. It is estimated that about 10 percent — or nearly 35 million adults in the United States alone have this embarrassing condition.

The PinPointe™ FootLaser™ is the only laser that has been clinically proven and has passed the rigorous testing by the FDA to receive clearance. Dr. Wolpa has successfully treated over 1600 patients and has seen dramatic results. “After many years of not having a successful way to treat my patients suffering with toenail fungus, I am thrilled to see such positive results using this leading edge laser technology,” says Dr. Wolpa.

About Bay Area Foot & Laser Podiatry Group

The Bay Area Foot & Laser Podiatry Group’s Dr. Mark Wolpa is Board Certified by the American Board of Podiatric Surgery and has been in practice in the Bay Area for over 30 years. He was the Chief of Podiatry at Alta Bates-Summit Hospital in Berkeley for the past 10 years and has authored articles, books, and appeared on radio and television programs discussing foot problems.

He has offices in Berkeley, Walnut Creek, Santa Rosa, and Marin. For more information about Dr. Wolpa and The PinPointe FootLaser visit www.BayAreaFootandLaser.com

Click here to see all recent news from this company

TUSTIN, CA–(Marketwire – October 28, 2010) –  Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the launch of the RPC Investor Channel — a new and innovative video website developed to enhance communications and corporate access for key audiences interested in RPC.

Through this dynamic mode of communication everyone from existing and prospective shareholders, the broad investment community at large, healthcare professionals and their patients can learn about Radient Pharmaceuticals and its portfolio of in vitro diagnostic (IVD) cancer tests and products. In addition, financial Advisors have the ability to distribute RPC Investor Channel content to clients and securely track consumption when campaigning to clients about RPC, enhancing Radient’s ability to scale consideration into new investor communities.

The site also features videos communicating RPC’s business model, target markets and international distribution, sales and growth strategy; RPC as an investment opportunity; updates and progress on RPC’s portfolio of cancer diagnostic products, including its FDA-approved Onko-Sure® IVD cancer test kit; and educational information specifically targeted towards patients, physicians and the healthcare community in general.

According to Mr. Douglas Maclellan, Executive Chairman and CEO of RPC, “As a publicly-traded Company, superior investor communications is of utmost importance to our executive management team. With the launch of RPC’s new Investor Relations Video Channel, we are expanding our traditional lines of communication to now include a multi-media platform that offers added flexibility, reach and the ability to disseminate relevant Company information in a ‘high-touch’. We are very excited to offer this service to our valued stakeholders.”

Videos are accessible and viewable through personal computers and handsets with a 3G connection by visiting http://investorchannel.radient-pharma.com. For additional information on Radient Pharmaceuticals and its portfolio of IVD cancer products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical’s current Onko-Sure® cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.Radient-Pharma.com.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

WINNIPEG, MANITOBA–(Marketwire – Oct. 27, 2010) – DiaMedica (TSX VENTURE:DMA) today announces that DM-199 has been validated by demonstrating significantly increased insulin sensitivity in animals using the hyperinsulemic euglycemic clamp model. Type 2 diabetes is a severely debilitating condition characterized by high blood sugar primarily due to a decrease in insulin sensitivity, which results in a number health problems including cardiovascular disease. 

The amount of glucose being processed in an animal model of type 2 diabetes with DM-199 was measured using the hyperinsulinemic euglycemic clamp, the gold standard method for characterizing the actions of insulin. Animals treated with a single dose of DM-199 had a 122% increase in maximal glucose infusion rate. This enabled animals to process 77% more total glucose compared to untreated animals. In a second study, DM-199 also had a pronounced anti-hypertensive effect on systolic blood pressure. This is important as approximately 70% of type 2 diabetes patients take multiple medications to treat high blood pressure.

“The clamp study clearly shows that treatment with DM-199 results in a major increase in insulin sensitivity in an animal model of type 2 diabetes. It is notable that the results of these studies actually provide an underestimate of the true effectiveness of DM-199. This is because the potency of DM-199 was so great that it was difficult to maintain the euglycemic clamp.” stated Dr. David Wasserman, Ron Santo Chair in Diabetes Research & Professor molecular physiology and biophysics at Vanderbilt University. “I very much look forward to seeing the future development of DM-199.”

“The results from both studies provide further validation of DM-199, our next generation form of DM-99, as a potential treatment for type 1 diabetes, type 2 diabetes and other diseases,” said Mr. Rick Pauls, CEO of DiaMedica. “This DM-199 data builds on compelling earlier animal and human proof of concept data with DM-99, and gives us confidence in moving forward with this very promising recombinant protein,” continued Mr. Pauls. “The dual benefits shown by DM-199 to increase the body’s ability to metabolize glucose and its positive effect on lowering systolic blood pressure may ultimately alleviate the need for diabetics to take multiple drugs for diabetes and hypertension.”

About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing novel treatments for type 1 diabetes, type 2 diabetes and other disorders. DiaMedica has completed two successful proof-of-concept Phase II studies with DM-71 and DM-99, which demonstrated human efficacy in lowering blood glucose levels in patients with type 2 diabetes.

DiaMedica’s lead product DM-199 is a novel recombinant next generation form of DM-99, which has shown the potential to increase insulin sensitivity, reduce the autoimmune attack and trigger proliferation of pancreatic beta cells, neural stem cells and bone marrow cells. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”. For further information please visit www.diamedica.com.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the anticipated use of proceeds from the Offering, management’s assessment of DiaMedica’s future plans, information with respect to the advancement of DiaMedica’s research and development programs, and DiaMedica’s other estimates and expectations. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our research and development programs, the availability of additional financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters.

Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2009 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions, which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of additional financing for research and development companies, and general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. 

NEW YORK, NY–(Marketwire – October 25, 2010) –  The market for infusion pumps has exceeded six billion dollars, which has encouraged over 100 companies to participate in the market, according to a recent report from healthcare market research publisher Kalorama Information. Kalorama’s new report, “Infusion Pump Markets (Large Volume, Ambulatory, Insulin, Enteral and Other Pumps),” estimates a worldwide market for infusion pumps of nearly $6.3 billion in 2010.

Infusion pumps are used to infuse necessary fluids, which include medications and/or nutrients, to a patient’s circulatory system, often where continuous monitoring and treatment by a nurse or other healthcare staff would be expensive, impractical, or unreliable. According to Kalorama Information, the market will increase just over three percent from last year due to growing competition in the field, declining hospital budgets and government restraints. But growth rates will be higher in specialty areas such as insulin delivery.

“This is a high dollar, low growth market with a lot of competition,” said Bruce Carlson, publisher of Kalorama Information. “That should be daunting for new entrants, but in the area of specialty pump markets there is more room for a niche player to develop and market a product.”

B. Braun, Care Fusion, Covidien and Hospira are among the large companies participating in this market. Medtronic is an example of a company that participates in the specialty areas of insulin infusion and implantable pumps. 

Profiles of key companies, market estimates and forecasts by product segment, as well as information on products and trends in the industry, can be found in Kalorama Information’s “Infusion Pump Markets (Large Volume, Ambulatory, Insulin, Enteral and Other Pumps).” The report is available at:
http://www.kaloramainformation.com/redirect.asp?progid=79883&productid=2824936.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://twitter.com/kaloramainfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

Click here to see all recent news from this company

BRAMPTON, ONTARIO–(Marketwire – 25 oct. 2010) – En vue d’élargir sa gamme de produits médicaux inédits sur le plan technologique pour la réparation de l’aorte par technique endovasculaire, la société Medtronic, Inc. (NYSE:MDT), a annoncé aujourd’hui le lancement au Canada du système Captivia(MC) pour la pose du greffon endoprothèse thoracique Valian(R), un traitement minimalement effractif des anévrismes et d’autres lésions de l’aorte thoracique. Le système de pose Captivia est offert à l’échelle internationale depuis l’automne 2009.

Le système de pose Captivia comporte un mécanisme de saisie des pointes rehaussant le contrôle du greffon endoprothèse thoracique Valiant lors de son déploiement, ainsi qu’un enduit hydrophile appliqué sur le greffon pour faciliter l’accès à l’artère iliaque et la pose de l’endoprothèse par le biais du système vasculaire des patients. Le nouveau système Captivia Valiant permet aux médecins de traiter facilement et avec précision un vaste éventail d’anatomies à l’aide d’un greffon endoprothèse ultraconfortable pour ainsi atteindre des résultats cliniques optimaux. Le système de greffon endoprothèse thoracique Valiant et le système de pose Captivia sont tous deux en phase de recherche aux États-Unis, alors que leur utilisation est restreinte aux essais cliniques approuvés par la Food and Drug Administration.

Le docteur François Dagenais, chirurgien cardiaque à l’Institut universitaire de cardiologie et de pneumologie de Québec, a effectué 17 implantations du greffon endoprothèse thoracique Valiant à l’aide du système de pose Captivia. Le docteur Dagenais est un chef de file de renommée mondiale en réparation endovasculaire thoracique; il a été un pionnier de ce traitement non effractif au Canada.

“Le système de pose Captivia de l’endogreffon thoracique Valiant permet un déploiement précis”, a expliqué le docteur Dagenais. “Particulièrement dans les limites d’un débit cardiaque élevé et d’un arc aortique angulé, le système Captivia minimise l’effet de manche à air et le déploiement asymétrique occasionnel associé à ce type d’intervention. Un tel mécanisme de dégagement contrôlé peut réduire le détachement embolique en réduisant la manipulation de l’arc et en prévenant le recouvrement par inadvertance de sa ramification. De plus, l’endogreffon Valiant du système Captivia est recouvert d’un enduit hydrophile facilitant son insertion dans l’artère iliaque serrée ou sinueuse.”

Indiqué pour le traitement de diverses lésions de l’aorte thoracique, le greffon endoprothèse thoracique Valiant s’est imposé comme le système minimalement effractif de choix pour la réparation de l’aorte thoracique par technique endovasculaire à l’extérieur des États-Unis. Après quatre années d’expérience clinique, plus de 15 000 patients ont ainsi reçu un greffon endoprothèse thoracique Valiant à l’échelle mondiale. 

“Compte tenu de l’adoption et de l’usage de plus en plus répandus de notre greffon endoprothèse thoracique Valiant, le système de pose Captivia constitue une autre amélioration procurant aux médecins un outil d’accès et de pose exceptionnellement simple, en plus de la précision et du contrôle lors du déploiement”, a déclaré M. Tony Semedo, vice-président et directeur général des Innovations endovasculaires, une unité intégrée au groupe des produits cardiovasculaires de Medtronic. “Lorsqu’on l’adjoint au greffon endoprothèse thoracique Valiant, qui se distingue toujours par sa grande conformité, le nouveau système élargit les possibilités de traitement endovasculaire pour inclure davantage de patients atteints de maladies complexes de l’aorte.”

À titre de pionnière de la technique endovasculaire pour les réparations de l’aorte, Medtronic est en tête de l’industrie des greffons endoprothèses depuis les années 90. Plus de 175 000 patients ont été traités à l’aide de ses dispositifs. La société propose la plus vaste gamme de greffons endoprothèses. De ceux-ci, mentionnons les greffons endoprothèses abdominaux et thoraciques Talent(R) offerts aux États-Unis, ainsi que les greffons abdominaux Endurant(R) et thoraciques Valiant(R) à l’extérieur des États-Unis.

Medtronic a comme mission de faire évoluer le traitement des maladies cardiovasculaires en collaboration avec les grands cliniciens, chercheurs et scientifiques du monde entier.

Au sujet de Medtronic

Medtronic, Inc. (www.medtronic.com), dont le siège social se trouve à Minneapolis, est le chef de file mondial de la technologie médicale visant à soulager la douleur, rétablir la santé et prolonger la vie de millions de gens, à l’échelle planétaire.

Au sujet de Medtronic du Canada Ltée 

Medtronic du Canada Ltée vend, entretien et distribue les produits de Medtronic au Canada : des instruments médicaux pour le traitement des maladies cardiaques et vasculaires et du diabète, pour la chirurgie de la colonne vertébrale, la neurochirurgie ainsi que pour la chirurgie oto-rhino-laryngologique. Medtronic du Canada, dont le siège social se trouve à Brampton, en Ontario, emploie quelque 420 Canadiens répartis dans son centre d’opérations de Mississauga, ses bureaux régionaux de Vancouver et Montréal. Elle exploite également une usine de mise au point et de fabrication de cathéters d’ablation pour la fibrillation auriculaire (FA) – Medtronic CryoCath – dans la région métropolitaine de Montréal.

Toutes les déclarations sur les résultats financiers anticipés sont assujetties à des risques et à des incertitudes, tels qu’ils sont énoncés dans les rapports périodiques de Medtronic déposés auprès de la Securities and Exchange Commission (Commission des valeurs mobilières des États-Unis). Les résultats réels pourraient différer sensiblement des résultats anticipés.

LUND, SWEDEN and LEIDEN, THE NETHERLANDS–(Marketwire – October 25, 2010) –  NeuroVive Pharmaceutical and to-BBB, the Dutch drug brain delivery company, are entering into a joint program to develop therapies for stroke and other acute neurodegenerative diseases by combining their technologies.

NeuroVive Pharmaceutical is engaged in research and development of nerve cell-protecting and regenerative cyclosporin-based pharmaceuticals for the treatment of traumatic brain injuries (TBI) and other neurological diseases. The Company’s first product NeuroSTAT®, is a novel, cremophor-free, cyclosporin-A lipid emulsion.

“The collaboration with to-BBB opens up the possibility of treating brain disorders beyond TBI. There is a tremendous unmet medical need in treating patients with acute neurodegeneration such as stroke, cardiac-arrest-induced brain damage and spinal cord injuries, where one can expect the blood-brain barrier (BBB) to significantly prevent drug penetration to the central nervous system (CNS)”, says Dr Eskil Elmér, CSO of NeuroVive.

Pieter Gaillard, CSO of to-BBB, adds: “The BBB is indeed a significant obstacle in the treatment of CNS disorders. to-BBB’s proprietary G-Technology^® can safely enhance drug delivery to the brain and we are excited to address this with NeuroVive’s cyclosporin-based pharmaceuticals”.

“Currently there are no approved pharmacological or cellular primary neuroprotective treatments for stroke and spinal cord injuries. Consequently, the need to develop treatment for acute degenerative disorders has never been greater than it is today. The deal with to-BBB has the potential to generate drugs for large markets in CNS diseases such as stroke”, says Mikael Brönnegård, CEO of NeuroVive.

“We are very pleased to collaborate with NeuroVive,” says Willem van Weperen, CEO of to-BBB. We are convinced that synergies in research and clinical platforms as well as business and commercial strategies between to-BBB and NeuroVive will result in a very strong partnership that will benefit patients with these devastating CNS diseases”.

NeuroVive is funding the initial development up to preclinical Proof of Concept, after which the two companies have agreed to develop and commercialize the product jointly.

About NeuroVive

NeuroVive Pharmaceutical AB is a Swedish drug development company. NeuroVive’s primary mission is to develop drugs which protect nerve cells. The company is currently conducting clinical trials with NeuroSTAT®. In addition to introducing NeuroSTAT® as the first cyclophilin-D-inhibiting mitochondrial protectant, NeuroVive is researching and developing variants of cyclophilin-inhibiting cyclosporins and new ways of transporting these drugs across the blood-brain barrier to the central nervous system. NeuroVive Pharmaceutical AB (publ) shares are listed on the Swedish trading platform AktieTorget (www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses and offers an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.

About to-BBB

to-BBB is a Dutch biotechnology company in the field of enhanced drug delivery across the blood-brain barrier. The company is developing novel treatments for brain disorders by combining existing drugs with its proprietary brain drug delivery platform. The company’s vision is that the treatment of currently unserved brain diseases will be best achieved by safely enhancing the blood-to-brain delivery of drugs.

to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.

EDMONTON, ALBERTA–(Marketwire – 21 oct. 2010) – Medtronic, Inc. (NYSE:MDT) a annoncé aujourd’hui le lancement au Canada d’une technologie inédite conçue pour assurer une protection accrue contre les risques associés à l’hypoglycémie. Ce nouveau dispositif, désormais offert au Canada ainsi que dans une cinquantaine de pays à l’extérieur des États-Unis, peut automatiquement interrompre l’administration de l’insuline lorsqu’il capte une chute ou des taux de glycémie inférieurs à un seuil présélectionné. La nouvelle fonction vise à réduire la gravité des crises d’hypoglycémie lorsque les patients oublient ou sont incapables d’y remédier. L’hypoglycémie, un composant dangereux et souvent fréquent du diabète, peut être l’un des aspects les plus effrayants du diabète de type 1. Non traitée, l’hypoglycémie peut causer la perte de conscience, une crise d’épilepsie, le coma ou même le décès.¹

Selon la recherche, une personne atteinte de diabète subit, en moyenne, plus d’une crise d’hypoglycémie aux deux semaines. En outre, environ un diabétique sur 14 traités par insuline vivra, chaque année, au moins une crise grave d’hypoglycémie nécessitant une intervention urgente de la part d’un professionnel de la santé.² Un tiers des diabétiques souffrent d’hypoglycémie pendant le sommeil et peuvent donc ne pas être en mesure de ressentir une crise grave ou de réagir pour la prévenir.³ On estime à 33 pour cent les cas de décès liés au diabète découlant de complications aiguës, comme l’hypoglycémie.⁴ Bien que la plupart des patients reconnaissent les «signes précoces» d’une hypoglycémie (dont la sensation de faiblesse, la sudation, le picotement des lèvres, la confusion et l’irritabilité), de nombreux autres peuvent ne rien ressentir du tout.

«La Paradigm Veo, grâce à son mécanisme automatique de rétroaction, représente un jalon important de notre engagement à améliorer le contrôle glycémique chez les diabétiques», a déclaré M^me Katie Szyman, présidente du groupe Diabète et vice-présidente principale de Medtronic. «Bien qu’il ne s’agisse pas d’une cure pour le diabète, nous croyons que cette fonction automatique rehausse la protection et la confiance et peut diminuer le risque de blessure associé aux crises d’hypoglycémie. Il importe tout autant de souligner la tranquillité d’esprit dont profiteront les patients et les membres de leur famille.»

Le système Paradigm Veo se compose d’une pompe à insuline et de la mesure du glucose en continu (MGC) (assurée par un capteur et un transmetteur distincts). Le patient se sert des lectures faites par le moniteur pour comprendre les tendances actuelles de sa glycémie. Après un prélèvement capillaire de confirmation, le patient programme la pompe à insuline pour qu’elle administre une quantité appropriée d’insuline. L’insuline combat l’hyperglycémie, l’une des principales causes des maladies cardiaques et d’autres complications à long terme du diabète de type 1.¹ Toutefois, si les données transmises par le capteur indiquent une chute de la glycémie sous un seuil déterminé à l’avance, l’instrument alerte le patient. Si ce dernier ignore ces signaux d’alarme, la pompe à insuline interrompt automatiquement l’administration d’insuline jusqu’à deux heures d’affilée. Cette fonction contribue ainsi à le protéger contre des périodes d’hypoglycémie potentiellement dangereuses. 

«Cette toute dernière technologie représente un jalon significatif. Elle aidera les diabétiques à optimiser le contrôle de leur glycémie de façon plus sécuritaire. Pour réduire le risque à long terme de complications liées au diabète, dont la cécité, l’insuffisance rénale et les crises cardiaques, les patients devraient maintenir leur glycémie à des taux les plus proches possibles de la normale. Malheureusement, un contrôle rigoureux de la glycémie accentue le risque d’hypoglycémie grave, ce qui peut rendre un patient inconscient et, en cas de crises répétées, peut avoir des conséquences très sérieuses», mentionne le docteur Bernard Zinman, directeur du Leadership Sinai Centre for Diabetes de l’Hôpital Mount Sinai de Toronto. «Pour la première fois, une pompe à insuline peut non seulement prévenir le patient de cette situation dangereuse, mais aussi y réagir pour ainsi corriger cette situation indésirable. Le système Paradigm Veo avertit les patients que leur glycémie est trop basse et arrête l’administration de plus ample quantité d’insuline s’ils ne réagissent pas à l’avertissement. Cette fonction de sécurité peut permettre aux patients de mieux contrôler leur hypoglycémie grave.»

Au sujet du groupe Diabète de Medtronic

Le groupe Diabète de Medtronic (www.medtronicdiabetes.com) est un chef de file mondial en solutions de pointe pour la gestion du diabète, notamment des systèmes intégrés de gestion du diabète, le traitement par pompe à insuline, des système de mesure du glucose en continu et un logiciel de gestion thérapeutique, ainsi que des services et un soutien hors pair à l’intention du grand public et des professionnels, 24 heures sur 24, 7 jours sur 7.

Au sujet de Medtronic

Medtronic, Inc. (www.medtronic.com), dont le siège social se trouve à Minneapolis, est le chef de file mondial de la technologie médicale visant à soulager la douleur, rétablir la santé et prolonger la vie de millions de gens, à l’échelle planétaire. De plus amples renseignements sont offerts sur : www.medtronic.com.

Toutes les déclarations sur les résultats financiers anticipés sont assujetties à des risques et à des incertitudes, tels qu’ils sont énoncés dans les rapports périodiques de Medtronic déposés auprès de la Securities and Exchange Commission (Commission des valeurs mobilières des États-Unis). Les résultats réels pourraient différer sensiblement des résultats anticipés.

Au sujet de Medtronic du Canada Ltée 

Medtronic du Canada Ltée, vend, entretient et distribue les produits de Medtronic au Canada : des instruments médicaux pour le traitement des maladies cardiaques et vasculaires et du diabète, pour la chirurgie de la colonne vertébrale, la neurochirurgie ainsi que pour la chirurgie oto-rhino-laryngologique. Medtronic du Canada, dont le siège social se trouve à Brampton, en Ontario, emploie plus de 420 Canadiens répartis dans son centre d’opérations de Mississauga et ses bureaux régionaux de Vancouver et Montréal. Elle exploite également une usine de mise au point et de fabrication de cathéters d’ablation pour la fibrillation auriculaire (FA) – Medtronic CryoCath – dans la région métropolitaine de Montréal.

Références

1. Diabetes UK: http://www.diabetes.org.uk/Guide-to-diabetes/Complications/Hypoglycaemia/ (Consulté le 23 avril 2009)

2. Leese GP, Wang J et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes. Diabetes Care 26:1176-1180, 2003.

3. Pramming S, Thorsteinsson B et al. Nocturnal hypoglycemia in patients receiving conventional treatment with insulin. British Medical Journal 291(1985):376-379

4. Orchard TJ. International evaluation of cause-specific mortality and IDDM. Diabetes Care 14:55-60, 1991